310 related articles for article (PubMed ID: 29088090)
1. Synthesis and Structure-Activity Relationships of 4-Morpholino-7,8-Dihydro-5H-Thiopyrano[4,3-d]pyrimidine Derivatives Bearing Pyrazoline Scaffold.
Wang Q; Li X; Sun C; Zhang B; Zheng P; Zhu W; Xu S
Molecules; 2017 Oct; 22(11):. PubMed ID: 29088090
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and anticancer activity of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives bearing chromone moiety.
Sun C; Chen C; Xu S; Wang J; Zhu Y; Kong D; Tao H; Jin M; Zheng P; Zhu W
Bioorg Med Chem; 2016 Aug; 24(16):3862-9. PubMed ID: 27353887
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, biological evaluation and docking studies of novel 2-substituted-4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as dual PI3Kα/mTOR inhibitors.
Lei F; Sun C; Xu S; Wang Q; OuYang Y; Chen C; Xia H; Wang L; Zheng P; Zhu W
Eur J Med Chem; 2016 Jun; 116():27-35. PubMed ID: 27043268
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as mTOR inhibitors.
Zhu W; Sun C; Xu S; Wu C; Wu J; Xu M; Zhao H; Chen L; Zeng W; Zheng P
Bioorg Med Chem; 2014 Dec; 22(24):6746-54. PubMed ID: 25468038
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
Wang L; Liu X; Duan Y; Li X; Zhao B; Wang C; Xiao Z; Zheng P; Tang Q; Zhu W
Chem Biol Drug Des; 2018 Jul; 92(1):1301-1314. PubMed ID: 29575727
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, and Biological Evaluation of Novel Thienopyrimidine Derivatives as PI3Kα Inhibitors.
Yu L; Wang Q; Wang C; Zhang B; Yang Z; Fang Y; Zhu W; Zheng P
Molecules; 2019 Sep; 24(19):. PubMed ID: 31547116
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Biological Evaluation of Novel 4-Morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine Derivatives Bearing Phenylpyridine/ Phenylpyrimidine-Carboxamides.
Liu H; Wang W; Sun C; Wang C; Zhu W; Zheng P
Molecules; 2016 Oct; 21(11):. PubMed ID: 27809261
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and antitumor evaluation of quinoline-imidazole derivatives.
Xiao Z; Lei F; Chen X; Wang X; Cao L; Ye K; Zhu W; Xu S
Arch Pharm (Weinheim); 2018 Jun; 351(6):e1700407. PubMed ID: 29732607
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα inhibitors.
Zhu W; Chen C; Sun C; Xu S; Wu C; Lei F; Xia H; Tu Q; Zheng P
Eur J Med Chem; 2015 Mar; 93():64-73. PubMed ID: 25659752
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis and Preliminary Biological Evaluation of Benzylsulfone Coumarin Derivatives as Anti-Cancer Agents.
Wang T; Peng T; Wen X; Wang G; Sun Y; Liu S; Zhang S; Wang L
Molecules; 2019 Nov; 24(22):. PubMed ID: 31703373
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of alkyl substituted pyridino[2,3-D]pyrimidine compounds as PI3Kα/mTOR dual inhibitors with improved pharmacokinetic properties and potent in vivo antitumor activity.
Liu Y; Xia Q; Fang L
Bioorg Med Chem; 2018 Aug; 26(14):3992-4000. PubMed ID: 29945756
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
Zhu W; Wang W; Xu S; Tang Q; Luo R; Wang M; Gong P; Zheng P
Bioorg Med Chem; 2016 Feb; 24(4):812-9. PubMed ID: 26810712
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors.
Wang W; Xu S; Duan Y; Liu X; Li X; Wang C; Zhao B; Zheng P; Zhu W
Eur J Med Chem; 2018 Feb; 145():315-327. PubMed ID: 29331754
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of novel condensed pyrrolo[1,2-c]pyrimidines featuring morpholine moiety as PI3Kα inhibitors.
Ibrahim MA; Abou-Seri SM; Hanna MM; Abdalla MM; El Sayed NA
Eur J Med Chem; 2015 Jun; 99():1-13. PubMed ID: 26037808
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Biological Evaluation of Novel 8-Morpholinoimidazo[1,2-a]pyrazine Derivatives Bearing Phenylpyridine/Phenylpyrimidine-Carboxamides.
Xu S; Sun C; Chen C; Zheng P; Zhou Y; Zhou H; Zhu W
Molecules; 2017 Feb; 22(2):. PubMed ID: 28218676
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold.
Wang M; Xu S; Lei H; Wang C; Xiao Z; Jia S; Zhi J; Zheng P; Zhu W
Bioorg Med Chem; 2017 Oct; 25(20):5754-5763. PubMed ID: 28927801
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and SAR of new-di-substituted pyridopyrimidines as ATP-competitive dual PI3Kα/mTOR inhibitors.
Al-Ashmawy AAK; Ragab FA; Elokely KM; Anwar MM; Perez-Leal O; Rico MC; Gordon J; Bichenkov E; Mateo G; Kassem EMM; Hegazy GH; Abou-Gharbia M; Childers W
Bioorg Med Chem Lett; 2017 Jul; 27(14):3117-3122. PubMed ID: 28571824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
